3-((6-fluoro-1-methyl-1H-indazol-5-yl)methyl)imidazo[1,2-b]pyridazine-6-carbaldehyde → 1-(3-((6-Fluoro-1-methyl-1H-indazol-5-yl)methyl)imidazo[1,2-b]pyridazin-6-yl)propan-1-ol
반응식
[F:1][C:2]1[CH:10]=[C:9]2[C:5]([CH:6]=[N:7][N:8]2[CH3:11])=[CH:4][C:3]=1[CH2:12][C:13]1[N:17]2[N:18]=[C:19]([CH:22]=[O:23])[CH:20]=[CH:21][C:16]2=[N:15][CH:14]=1.[CH2:24]([Mg]Br)[CH3:25]>C1COCC1>[F:1][C:2]1[CH:10]=[C:9]2[C:5]([CH:6]=[N:7][N:8]2[CH3:11])=[CH:4][C:3]=1[CH2:12][C:13]1[N:17]2[N:18]=[C:19]([CH:22]([OH:23])[CH2:24][CH3:25])[CH:20]=[CH:21][C:16]2=[N:15][CH:14]=1참가 물질
4
실험 절차
To a solution of 3-((6-fluoro-1-methyl-1H-indazol-5-yl)methyl)imidazo[1,2-b]pyridazine-6-carbaldehyde (52 mg, 0.168 mmol) in THF (4 mL) at 0° C., was added a solution of ethylmagnesium bromide in THF (1M, 0.336 mL) dropwise. After stirring for 16 h, the reaction mixture was quenched with NH4Cl(aq), extracted with EtOAc, dried over Na2SO4. Filtered through Celite and concentrated in vacuo to give a crude product (14 mg, 10%). LCMS (method B): [MH]+=340, tR=2.04 min.